Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,11489805,ne,"The mean +/- SD neutrophil survival fraction at nadir for the POG, POG+G, and NHP groups was 0.12 +/- 0.09, 0.11 +/- 0.17, and 0.09 +/- 0.08, respectively (P > 0.05).",Pharmacodynamic model of topotecan-induced time course of neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11489805/),,0.12,16672,DB00099,Filgrastim
,11489805,ne,"The mean +/- SD neutrophil survival fraction at nadir for the POG, POG+G, and NHP groups was 0.12 +/- 0.09, 0.11 +/- 0.17, and 0.09 +/- 0.08, respectively (P > 0.05).",Pharmacodynamic model of topotecan-induced time course of neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11489805/),,0.11,16673,DB00099,Filgrastim
,11489805,survival fraction,"The mean +/- SD neutrophil survival fraction at nadir for the POG, POG+G, and NHP groups was 0.12 +/- 0.09, 0.11 +/- 0.17, and 0.09 +/- 0.08, respectively (P > 0.05).",Pharmacodynamic model of topotecan-induced time course of neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11489805/),,0.12,16674,DB00099,Filgrastim
,11489805,survival fraction,"The mean +/- SD neutrophil survival fraction at nadir for the POG, POG+G, and NHP groups was 0.12 +/- 0.09, 0.11 +/- 0.17, and 0.09 +/- 0.08, respectively (P > 0.05).",Pharmacodynamic model of topotecan-induced time course of neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11489805/),,0.11,16675,DB00099,Filgrastim
,11489805,survival fraction,"The mean +/- SD neutrophil survival fraction at nadir for the POG, POG+G, and NHP groups was 0.12 +/- 0.09, 0.11 +/- 0.17, and 0.09 +/- 0.08, respectively (P > 0.05).",Pharmacodynamic model of topotecan-induced time course of neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11489805/),,0.09,16676,DB00099,Filgrastim
,12458679,"t(1/2,term)","The t(1/2,term), MRT, and CL/F of Albugranin following SC administration to BDF1 mice were 5.6-5.7 h, 16.7-20.7 h, and 6.37-12.2 mL/h/kg, respectively, compared with 2.54 h, 4.9 h, and 164 mL/h/kg, respectively for Filgrastim.","Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12458679/),h,5,17423,DB00099,Filgrastim
,12458679,MRT,"The t(1/2,term), MRT, and CL/F of Albugranin following SC administration to BDF1 mice were 5.6-5.7 h, 16.7-20.7 h, and 6.37-12.2 mL/h/kg, respectively, compared with 2.54 h, 4.9 h, and 164 mL/h/kg, respectively for Filgrastim.","Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12458679/),h,16.7-20.7,17424,DB00099,Filgrastim
,12458679,MRT,"The t(1/2,term), MRT, and CL/F of Albugranin following SC administration to BDF1 mice were 5.6-5.7 h, 16.7-20.7 h, and 6.37-12.2 mL/h/kg, respectively, compared with 2.54 h, 4.9 h, and 164 mL/h/kg, respectively for Filgrastim.","Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12458679/),[ml] / [h·kg],6.37-12.2,17425,DB00099,Filgrastim
,12458679,MRT,"The t(1/2,term), MRT, and CL/F of Albugranin following SC administration to BDF1 mice were 5.6-5.7 h, 16.7-20.7 h, and 6.37-12.2 mL/h/kg, respectively, compared with 2.54 h, 4.9 h, and 164 mL/h/kg, respectively for Filgrastim.","Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12458679/),h,2.54,17426,DB00099,Filgrastim
,12458679,MRT,"The t(1/2,term), MRT, and CL/F of Albugranin following SC administration to BDF1 mice were 5.6-5.7 h, 16.7-20.7 h, and 6.37-12.2 mL/h/kg, respectively, compared with 2.54 h, 4.9 h, and 164 mL/h/kg, respectively for Filgrastim.","Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12458679/),h,4.9,17427,DB00099,Filgrastim
,12458679,CL/F,"The t(1/2,term), MRT, and CL/F of Albugranin following SC administration to BDF1 mice were 5.6-5.7 h, 16.7-20.7 h, and 6.37-12.2 mL/h/kg, respectively, compared with 2.54 h, 4.9 h, and 164 mL/h/kg, respectively for Filgrastim.","Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12458679/),[ml] / [h·kg],6.37-12.2,17428,DB00099,Filgrastim
,12458679,CL/F,"The t(1/2,term), MRT, and CL/F of Albugranin following SC administration to BDF1 mice were 5.6-5.7 h, 16.7-20.7 h, and 6.37-12.2 mL/h/kg, respectively, compared with 2.54 h, 4.9 h, and 164 mL/h/kg, respectively for Filgrastim.","Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12458679/),h,2.54,17429,DB00099,Filgrastim
,12458679,CL/F,"The t(1/2,term), MRT, and CL/F of Albugranin following SC administration to BDF1 mice were 5.6-5.7 h, 16.7-20.7 h, and 6.37-12.2 mL/h/kg, respectively, compared with 2.54 h, 4.9 h, and 164 mL/h/kg, respectively for Filgrastim.","Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12458679/),[ml] / [h·kg],164,17430,DB00099,Filgrastim
,12458679,t(1/2,"In cynomolgus monkeys, the corresponding values of t(1/2,term), MRT, and CL/F for Albugranin were 7.73-133 h, 19.4-27.3 h, and 7.90-27.5 mL/h/kg, respectively, for doses of 100-1000 microg/kg.","Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12458679/),h,7.73-133,17431,DB00099,Filgrastim
,12458679,term),"In cynomolgus monkeys, the corresponding values of t(1/2,term), MRT, and CL/F for Albugranin were 7.73-133 h, 19.4-27.3 h, and 7.90-27.5 mL/h/kg, respectively, for doses of 100-1000 microg/kg.","Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12458679/),h,19.4-27.3,17432,DB00099,Filgrastim
,12458679,MRT,"In cynomolgus monkeys, the corresponding values of t(1/2,term), MRT, and CL/F for Albugranin were 7.73-133 h, 19.4-27.3 h, and 7.90-27.5 mL/h/kg, respectively, for doses of 100-1000 microg/kg.","Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. ",MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12458679/),h,19.4-27.3,17433,DB00099,Filgrastim
,12458679,CL/F,"In cynomolgus monkeys, the corresponding values of t(1/2,term), MRT, and CL/F for Albugranin were 7.73-133 h, 19.4-27.3 h, and 7.90-27.5 mL/h/kg, respectively, for doses of 100-1000 microg/kg.","Albugranin, a recombinant human granulocyte colony stimulating factor (G-CSF) genetically fused to recombinant human albumin induces prolonged myelopoietic effects in mice and monkeys. ",CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12458679/),[ml] / [h·kg],7.90-27.5,17434,DB00099,Filgrastim
,12560443,duration,"In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively).","Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12560443/),d,2.8,20431,DB00099,Filgrastim
,12560443,duration,"In addition, the mean duration of grade 4 neutropenia was similar in both groups (2.8 and 2.4 days, respectively).","Randomized, multicenter, open-label study of pegfilgrastim compared with daily filgrastim after chemotherapy for lymphoma. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12560443/),d,2.4,20432,DB00099,Filgrastim
,9815739,plasma half-life (t1/2),"Mean plasma half-life (t1/2) in the 4-h infusion group was 197 min, and the volume of distribution approximated plasma volume.",Clinical pharmacology of filgrastim following high-dose chemotherapy and autologous bone marrow transplantation. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9815739/),min,197,26548,DB00099,Filgrastim
,17235504,absolute neutrophil nadir,Median absolute neutrophil nadir was 0.32 g/l on day 9.,Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17235504/),[g] / [l],0.32,32738,DB00099,Filgrastim
,17235504,trough plasma level,Median pegfilgrastim trough plasma level was 0.43 ng/ml on the day preceding the next application.,Pegfilgrastim as hematopoietic support for dose-dense chemoimmunotherapy with R-CHOP-14 as first-line therapy in elderly patients with diffuse large B cell lymphoma. ,Ctrough-Q37,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17235504/),[ng] / [ml],0.43,32739,DB00099,Filgrastim
,17545847,area under the curve (AUC),Chemotherapy-naïve patients with locally advanced or metastatic NSCLC were treated with carboplatin area under the curve (AUC) 6 mg/ml per minute intravenously on day 1 and vinorelbine 30 mg/m2 intravenously on days 1 and 8 every 3 weeks for four planned cycles.,A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545847/),[mg] / [min·ml],6,36914,DB00099,Filgrastim
,17545847,Overall response rate,Overall response rate was 27%.,A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545847/),%,27,36915,DB00099,Filgrastim
,17545847,survival,Median survival was 9.4 months (95% confidence interval: 6.1-18.0) with a 3-year survival rate of 20%.,A phase II trial of carboplatin/vinorelbine with pegfilgrastim support for the treatment of patients with advanced non-small cell lung cancer. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17545847/),month,9,36916,DB00099,Filgrastim
,11677930,Emax,A sigmoidal Emax model for the stimulation of ANC input rate (kin) was superior to the conventional Emax model (mean +/- SE: Emax = 12.7 +/- 1.7; EC50 = 4.72 +/- 0.72 ng/ml; Hill = 1.34 +/- 0.19).,Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. ,Emax-Q15,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11677930/),,12.7,48660,DB00099,Filgrastim
,11677930,EC50,A sigmoidal Emax model for the stimulation of ANC input rate (kin) was superior to the conventional Emax model (mean +/- SE: Emax = 12.7 +/- 1.7; EC50 = 4.72 +/- 0.72 ng/ml; Hill = 1.34 +/- 0.19).,Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. ,EC50-Q16,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11677930/),[ng] / [ml],4.72,48661,DB00099,Filgrastim
,11677930,Hill,A sigmoidal Emax model for the stimulation of ANC input rate (kin) was superior to the conventional Emax model (mean +/- SE: Emax = 12.7 +/- 1.7; EC50 = 4.72 +/- 0.72 ng/ml; Hill = 1.34 +/- 0.19).,Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11677930/),,1.34,48662,DB00099,Filgrastim
,11677930,absolute bioavailability,"The absolute bioavailability of subcutaneously administered Filgrastim was estimated to be 0.619 +/- 0.058 and 0.717 +/- 0.028 for 375 micrograms and 750 micrograms s.c. doses, respectively.",Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11677930/),,0.619,48663,DB00099,Filgrastim
,11677930,absolute bioavailability,"The absolute bioavailability of subcutaneously administered Filgrastim was estimated to be 0.619 +/- 0.058 and 0.717 +/- 0.028 for 375 micrograms and 750 micrograms s.c. doses, respectively.",Population pharmacokinetic-pharmacodynamic modeling of filgrastim (r-metHuG-CSF) in healthy volunteers. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11677930/),,0.717,48664,DB00099,Filgrastim
,15583936,time to leukocyte recovery,"Mean time to leukocyte recovery was 10.7 days (SD+/-0.9) (lenograstim) and 10.8 days (SD+/-0.6) (filgrastim), respectively.",Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15583936/),d,10.7,52325,DB00099,Filgrastim
,15583936,time to leukocyte recovery,"Mean time to leukocyte recovery was 10.7 days (SD+/-0.9) (lenograstim) and 10.8 days (SD+/-0.6) (filgrastim), respectively.",Comparison of lenograstim and filgrastim: effects on blood cell recovery after high-dose chemotherapy and autologous peripheral blood stem cell transplantation. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15583936/),d,10.8,52326,DB00099,Filgrastim
≥,22991919,time to recovery to an absolute neutrophil count,"Pharmacokinetic parameters and neutrophil-related values for duration of neutropenia, neutrophil nadir, time to recovery to an absolute neutrophil count ≥500/μL or ≥2000/μL, and days of antibiotic support were determined.","Pegfilgrastim administered in an abbreviated schedule, significantly improved neutrophil recovery after high-dose radiation-induced myelosuppression in rhesus macaques. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22991919/),,500,54709,DB00099,Filgrastim
,9773805,MTD,The MTD of the 96 h paclitaxel infusion was 180 mg/m2 with filgrastim support.,Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9773805/),[mg] / [m2],180,58252,DB00099,Filgrastim
greater,9773805,steady-state paclitaxel concentrations (Css),Mucosal and granulocyte toxicity were correlated with steady-state paclitaxel concentrations (Css) greater than 0.100 micromol/l.,Phase I trial of a 96 h paclitaxel infusion with filgrastim support in refractory solid tumor patients. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9773805/),[μM] / [l],0.100,58253,DB00099,Filgrastim
,9213323,MTDs,The MTDs for patients with a history of prior chemotherapy were 75 mg/m2 of docetaxel and 700 mg/m2 of cyclophosphamide.,Docetaxel and cyclophosphamide in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9213323/),[mg] / [m2],75,60319,DB00099,Filgrastim
,9213323,MTDs,The MTDs for patients with a history of prior chemotherapy were 75 mg/m2 of docetaxel and 700 mg/m2 of cyclophosphamide.,Docetaxel and cyclophosphamide in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9213323/),[mg] / [m],700,60320,DB00099,Filgrastim
,9213323,MTDs,"For patients with no prior chemotherapy, the MTDs were 75 mg/m2 of docetaxel and 800 mg/m2 of cyclophosphamide.",Docetaxel and cyclophosphamide in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9213323/),[mg] / [m],75,60321,DB00099,Filgrastim
,11822765,terminal half-lives,"The harmonic mean terminal half-lives for CPT-11, SN-38, and SN-38G were 7.1 hours, 13.4 hours, and 12.7 hours, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822765/),h,7.1,81659,DB00099,Filgrastim
,11822765,terminal half-lives,"The harmonic mean terminal half-lives for CPT-11, SN-38, and SN-38G were 7.1 hours, 13.4 hours, and 12.7 hours, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822765/),h,13.4,81660,DB00099,Filgrastim
,11822765,terminal half-lives,"The harmonic mean terminal half-lives for CPT-11, SN-38, and SN-38G were 7.1 hours, 13.4 hours, and 12.7 hours, respectively.",Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822765/),h,12.7,81661,DB00099,Filgrastim
,11822765,clearance,"Across the range of doses studied, mean CPT-11 clearance was 14.0 +/- 4.0 l/h/m2 and volume of distribution was 146 +/- 45.9 l/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822765/),[l] / [h·m2],14.0,81662,DB00099,Filgrastim
,11822765,volume of distribution,"Across the range of doses studied, mean CPT-11 clearance was 14.0 +/- 4.0 l/h/m2 and volume of distribution was 146 +/- 45.9 l/m2.",Phase I dose-finding and pharmacokinetic trial of irinotecan (CPT-11) administered every two weeks. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11822765/),[l] / [m2],146,81663,DB00099,Filgrastim
,25672916,MTDs,The MTDs for buparlisib were 100 mg/day in Group 1 and 80 mg/day in Group 2.,Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25672916/),[mg] / [d],100,91206,DB00099,Filgrastim
,25672916,MTDs,The MTDs for buparlisib were 100 mg/day in Group 1 and 80 mg/day in Group 2.,Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25672916/),[mg] / [d],80,91207,DB00099,Filgrastim
,25672916,objective response rate,"Among 25 patients with measurable disease, the confirmed objective response rate was 20% (one complete response, four partial responses).",Parallel phase Ib studies of two schedules of buparlisib (BKM120) plus carboplatin and paclitaxel (q21 days or q28 days) for patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25672916/),%,20,91208,DB00099,Filgrastim
,12721265,terminal half-life,"The mean terminal half-life of BMS-247550 was 16.8 +/- 6.0 hours, the volume of distribution at steady-state was 798 +/- 375 L, and the clearance was 712 +/- 247 mL/min.","Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721265/),h,16.8,92005,DB00099,Filgrastim
,12721265,volume of distribution at steady-state,"The mean terminal half-life of BMS-247550 was 16.8 +/- 6.0 hours, the volume of distribution at steady-state was 798 +/- 375 L, and the clearance was 712 +/- 247 mL/min.","Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. ",Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721265/),l,798,92006,DB00099,Filgrastim
,12721265,clearance,"The mean terminal half-life of BMS-247550 was 16.8 +/- 6.0 hours, the volume of distribution at steady-state was 798 +/- 375 L, and the clearance was 712 +/- 247 mL/min.","Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12721265/),[ml] / [min],712,92007,DB00099,Filgrastim
,19920107,apparent clearance,Pegfilgrastim apparent clearance (11 mL/h/kg) was similar to that reported in adults.,Randomized trial and pharmacokinetic study of pegfilgrastim versus filgrastim after dose-intensive chemotherapy in young adults and children with sarcomas. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19920107/),[ml] / [h·kg],11,98475,DB00099,Filgrastim
,18524995,C(max),No discernable correlation between pharmacokinetic parameter values and degree of renal impairment was observed; the mean values ranged from 147 to 201 ng/mL for C(max) and from 7469 to 8513 ng x h/mL for AUC.,Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18524995/),[ng] / [ml],147 to 201,100304,DB00099,Filgrastim
,18524995,AUC,No discernable correlation between pharmacokinetic parameter values and degree of renal impairment was observed; the mean values ranged from 147 to 201 ng/mL for C(max) and from 7469 to 8513 ng x h/mL for AUC.,Pharmacokinetics and pharmacodynamics of pegfilgrastim in subjects with various degrees of renal function. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18524995/),[h·ng] / [ml],7469 to 8513,100305,DB00099,Filgrastim
,11279634,Time to reach peak concentration (T(max)),"Time to reach peak concentration (T(max)) and half-life of Ro 25-8315 averaged 20-30 hr at all doses, approximately three times longer than with Filgrastim.",Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11279634/),h,20-30,103927,DB00099,Filgrastim
,10080614,areas under the concentration time curve (AUCs),"Paclitaxel was initially administered as a 24-hour infusion at a fixed dose of 135 mg/m2, and the carboplatin dose was escalated in cohorts of three patients, using Calvert's formula [dose(mg) = area under the concentration time curve (glomerular filtration rate + 25)], to target areas under the concentration time curve (AUCs) of 5, 7, 9, and 11 mg/mL x minute.","Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],5,104363,DB00099,Filgrastim
,10080614,areas under the concentration time curve (AUCs),"Paclitaxel was initially administered as a 24-hour infusion at a fixed dose of 135 mg/m2, and the carboplatin dose was escalated in cohorts of three patients, using Calvert's formula [dose(mg) = area under the concentration time curve (glomerular filtration rate + 25)], to target areas under the concentration time curve (AUCs) of 5, 7, 9, and 11 mg/mL x minute.","Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],7,104364,DB00099,Filgrastim
,10080614,areas under the concentration time curve (AUCs),"Paclitaxel was initially administered as a 24-hour infusion at a fixed dose of 135 mg/m2, and the carboplatin dose was escalated in cohorts of three patients, using Calvert's formula [dose(mg) = area under the concentration time curve (glomerular filtration rate + 25)], to target areas under the concentration time curve (AUCs) of 5, 7, 9, and 11 mg/mL x minute.","Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],9,104365,DB00099,Filgrastim
,10080614,areas under the concentration time curve (AUCs),"Paclitaxel was initially administered as a 24-hour infusion at a fixed dose of 135 mg/m2, and the carboplatin dose was escalated in cohorts of three patients, using Calvert's formula [dose(mg) = area under the concentration time curve (glomerular filtration rate + 25)], to target areas under the concentration time curve (AUCs) of 5, 7, 9, and 11 mg/mL x minute.","Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],11,104366,DB00099,Filgrastim
,10080614,AUC,Thrombocytopenia was observed at a carboplatin AUC of 11 mg/mL x minute after course 2 and thereafter.,"Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],11,104367,DB00099,Filgrastim
,10080614,duration of time,End-of-infusion plasma paclitaxel concentrations and median duration of time above 0.05 microM were similar in course 1 versus course 2 at the 135 and 175 mg/m2 dose levels.,"Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),μM,0,104368,DB00099,Filgrastim
,10080614,overall response rate,"Of the 36 patients entered onto the study, one experienced a complete response and 17 had partial responses, for an overall response rate of 50%.","Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),%,50,104369,DB00099,Filgrastim
,10080614,AUC,The recommended doses of paclitaxel (24-hour infusion) and carboplatin for future phase II studies of this combination are (1) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute without filgrastim support; (2) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 9 mg/mL x minute with filgrastim support; and (3) paclitaxel 225 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute with filgrastim support.,"Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],7,104370,DB00099,Filgrastim
,10080614,AUC,The recommended doses of paclitaxel (24-hour infusion) and carboplatin for future phase II studies of this combination are (1) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute without filgrastim support; (2) paclitaxel 135 mg/m2 with a carboplatin dose targeted to achieve an AUC of 9 mg/mL x minute with filgrastim support; and (3) paclitaxel 225 mg/m2 with a carboplatin dose targeted to achieve an AUC of 7 mg/mL x minute with filgrastim support.,"Phase I trial, including pharmacokinetic and pharmacodynamic correlations, of combination paclitaxel and carboplatin in patients with metastatic non-small-cell lung cancer. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10080614/),[mg] / [min·ml],9,104371,DB00099,Filgrastim
,25684345,half-life,The half-life for filanesib was ~70 h.,"First-in-human phase 1 study of filanesib (ARRY-520), a kinesin spindle protein inhibitor, in patients with advanced solid tumors. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25684345/),h,70,106193,DB00099,Filgrastim
,9331121,area under the concentration-time curve (AUC),A phase I trial performed at the University of North Carolina was designed to evaluate paclitaxel 250 mg/m2 given over 24 hours plus escalating doses of carboplatin starting at an area under the concentration-time curve (AUC) dose of 8 supported by peripheral blood stem cells and filgrastim in the treatment of advanced NSCLC.,High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331121/),,8,106755,DB00099,Filgrastim
,9331121,AUC,The maximum tolerated dose of carboplatin combined with paclitaxel 250 mg/m2 administered over 24 hours was defined at an AUC of 18.,High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331121/),,18,106756,DB00099,Filgrastim
,9331121,AUC,This regimen is currently being tested in patients with locally advanced NSCLC by the Cancer and Leukemia Group B: patients receive two cycles of induction therapy with paclitaxel 250 mg/m2 over 3 hours followed by carboplatin at an AUC of 18 supported by peripheral blood stem cells and filgrastim.,High-dose therapy with carboplatin and paclitaxel in non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9331121/),,18,106757,DB00099,Filgrastim
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,2.7,109481,DB00099,Filgrastim
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,2,109482,DB00099,Filgrastim
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,1.3,109483,DB00099,Filgrastim
,12123336,duration of,"Mean duration of grade 4 neutropenia in cycle 1 was 2.7,2 and 1.3 days for doses of pegfilgrastim, and 1.6 days for filgrastim.",Comparable efficacy and safety profiles of once-per-cycle pegfilgrastim and daily injection filgrastim in chemotherapy-induced neutropenia: a multicenter dose-finding study in women with breast cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12123336/),d,1.6,109484,DB00099,Filgrastim
,16982322,Peak levels,Peak levels were reached at day +4 (94 ng/mL; range: 37-205) and were maintained until day +7 (85 ng/mL; range: 35-186).,Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982322/),[ng] / [ml],94,115134,DB00099,Filgrastim
,16982322,Peak levels,Peak levels were reached at day +4 (94 ng/mL; range: 37-205) and were maintained until day +7 (85 ng/mL; range: 35-186).,Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982322/),[ng] / [ml],85,115135,DB00099,Filgrastim
,16982322,time to neutrophil reconstitution,"Comparison with the control group without G-CSF support showed that time to neutrophil reconstitution was significantly shorter in the pegfilgrastim group with 10 vs 15 days, respectively (p < 0.001).",Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982322/),d,10,115136,DB00099,Filgrastim
,16982322,time to neutrophil reconstitution,"Comparison with the control group without G-CSF support showed that time to neutrophil reconstitution was significantly shorter in the pegfilgrastim group with 10 vs 15 days, respectively (p < 0.001).",Sustained G-CSF plasma levels following administration of pegfilgrastim fasten neutrophil reconstitution after high-dose chemotherapy and autologous blood stem cell transplantation in patients with multiple myeloma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16982322/),d,15,115137,DB00099,Filgrastim
,32567217,area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ),"The mean area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ) and the mean maximum concentration (Cmax ) of PEG-rhG-CSF after treatment A were 5070 ng·h/mL and 125 ng/mL, respectively; these values were comparable to those measured after treatment B (5340 ng·h/mL and 123 ng/mL, respectively).","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[h·ng] / [ml],5070,137540,DB00099,Filgrastim
,32567217,area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ),"The mean area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ) and the mean maximum concentration (Cmax ) of PEG-rhG-CSF after treatment A were 5070 ng·h/mL and 125 ng/mL, respectively; these values were comparable to those measured after treatment B (5340 ng·h/mL and 123 ng/mL, respectively).","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[h·ng] / [ml],5340,137541,DB00099,Filgrastim
,32567217,area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ),"The mean area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ) and the mean maximum concentration (Cmax ) of PEG-rhG-CSF after treatment A were 5070 ng·h/mL and 125 ng/mL, respectively; these values were comparable to those measured after treatment B (5340 ng·h/mL and 123 ng/mL, respectively).","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[ng] / [ml],123,137542,DB00099,Filgrastim
,32567217,maximum concentration (Cmax ),"The mean area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ) and the mean maximum concentration (Cmax ) of PEG-rhG-CSF after treatment A were 5070 ng·h/mL and 125 ng/mL, respectively; these values were comparable to those measured after treatment B (5340 ng·h/mL and 123 ng/mL, respectively).","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[ng] / [ml],125,137543,DB00099,Filgrastim
,32567217,maximum concentration (Cmax ),"The mean area under the concentration-time curve from time zero to the last quantifiable concentration (AUC0-t ) and the mean maximum concentration (Cmax ) of PEG-rhG-CSF after treatment A were 5070 ng·h/mL and 125 ng/mL, respectively; these values were comparable to those measured after treatment B (5340 ng·h/mL and 123 ng/mL, respectively).","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[ng] / [ml],123,137544,DB00099,Filgrastim
,32567217,area under the △ANC,"The mean value of area under the △ANC (baseline-adjusted ANC)-time curve and the maximum △ANC values were 4380 × 109 h/L and 33.1 × 109 /L, respectively, in the treatment A group, and 5170 × 109 h/L and 38.6 × 109 /L, respectively, in the treatment B group.","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[h] / [l],4380 ×,137545,DB00099,Filgrastim
,32567217,area under the △ANC,"The mean value of area under the △ANC (baseline-adjusted ANC)-time curve and the maximum △ANC values were 4380 × 109 h/L and 33.1 × 109 /L, respectively, in the treatment A group, and 5170 × 109 h/L and 38.6 × 109 /L, respectively, in the treatment B group.","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[h] / [l],5170,137546,DB00099,Filgrastim
,32567217,maximum △ANC,"The mean value of area under the △ANC (baseline-adjusted ANC)-time curve and the maximum △ANC values were 4380 × 109 h/L and 33.1 × 109 /L, respectively, in the treatment A group, and 5170 × 109 h/L and 38.6 × 109 /L, respectively, in the treatment B group.","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),,33.1 ×,137547,DB00099,Filgrastim
,32567217,maximum △ANC,"The mean value of area under the △ANC (baseline-adjusted ANC)-time curve and the maximum △ANC values were 4380 × 109 h/L and 33.1 × 109 /L, respectively, in the treatment A group, and 5170 × 109 h/L and 38.6 × 109 /L, respectively, in the treatment B group.","Pharmacokinetics and Pharmacodynamics of Two Formulations of Pegylated Recombinant Human Granulocyte Colony-Stimulating Factor in Healthy Chinese Subjects: An Open-Label, Randomized, Parallel-Design Bioavailability Study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32567217/),[109] / [l],38.6,137548,DB00099,Filgrastim
,11334057,Maximum levels,Maximum levels of PEG-rHuMGDF attained after 5.0 microg/kg/day were 5.88 to 10.9 ng/mL.,Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334057/),[ng] / [ml],5.88 to 10.9,137827,DB00099,Filgrastim
,11334057,terminal half-life,"The mean terminal half-life was 33.3 + 16.7 hours, and the average apparent at steady state was 27.7 + 14.0 mL/h/kg; both were independent of administered dose.",Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334057/),h,33.3,137828,DB00099,Filgrastim
,11334057,apparent at steady state,"The mean terminal half-life was 33.3 + 16.7 hours, and the average apparent at steady state was 27.7 + 14.0 mL/h/kg; both were independent of administered dose.",Pharmacokinetic analysis of pegylated megakaryocyte growth and development factor in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11334057/),[ml] / [h·kg],27.7,137829,DB00099,Filgrastim
,9523740,distribution half-life,"The mean fast distribution half-life (1.5 +/- 1.0 min) and the mean plasma clearance (2.18 +/- 0.95 l/min) were significantly lower than the respective mean values found in a previous study in which 27 patients had received MX2 (16.8-107.5 mg) alone (3.3 +/- 2.2 min and 2.98 +/- 1.68 l/min, respectively; P < 0.05).",Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523740/),min,1.5,138437,DB00099,Filgrastim
,9523740,plasma clearance,"The mean fast distribution half-life (1.5 +/- 1.0 min) and the mean plasma clearance (2.18 +/- 0.95 l/min) were significantly lower than the respective mean values found in a previous study in which 27 patients had received MX2 (16.8-107.5 mg) alone (3.3 +/- 2.2 min and 2.98 +/- 1.68 l/min, respectively; P < 0.05).",Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523740/),[l] / [min],2.18,138438,DB00099,Filgrastim
,9523740,plasma clearance,"The mean fast distribution half-life (1.5 +/- 1.0 min) and the mean plasma clearance (2.18 +/- 0.95 l/min) were significantly lower than the respective mean values found in a previous study in which 27 patients had received MX2 (16.8-107.5 mg) alone (3.3 +/- 2.2 min and 2.98 +/- 1.68 l/min, respectively; P < 0.05).",Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523740/),min,3.3,138439,DB00099,Filgrastim
,9523740,plasma clearance,"The mean fast distribution half-life (1.5 +/- 1.0 min) and the mean plasma clearance (2.18 +/- 0.95 l/min) were significantly lower than the respective mean values found in a previous study in which 27 patients had received MX2 (16.8-107.5 mg) alone (3.3 +/- 2.2 min and 2.98 +/- 1.68 l/min, respectively; P < 0.05).",Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523740/),[l] / [min],2.98,138440,DB00099,Filgrastim
,9523740,Elimination half-lives,"Elimination half-lives of the metabolites M1 and M4 were significantly greater in the filgrastim group (19.8 +/- 14.7 and 11.8 +/- 5.0 h for M1 and 14.8 +/- 4.1 and 12.3 +/- 6.3 h for M2, respectively).",Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523740/),h,19.8,138441,DB00099,Filgrastim
,9523740,Elimination half-lives,"Elimination half-lives of the metabolites M1 and M4 were significantly greater in the filgrastim group (19.8 +/- 14.7 and 11.8 +/- 5.0 h for M1 and 14.8 +/- 4.1 and 12.3 +/- 6.3 h for M2, respectively).",Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523740/),h,11.8,138442,DB00099,Filgrastim
,9523740,Elimination half-lives,"Elimination half-lives of the metabolites M1 and M4 were significantly greater in the filgrastim group (19.8 +/- 14.7 and 11.8 +/- 5.0 h for M1 and 14.8 +/- 4.1 and 12.3 +/- 6.3 h for M2, respectively).",Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523740/),h,14.8,138443,DB00099,Filgrastim
,9523740,Elimination half-lives,"Elimination half-lives of the metabolites M1 and M4 were significantly greater in the filgrastim group (19.8 +/- 14.7 and 11.8 +/- 5.0 h for M1 and 14.8 +/- 4.1 and 12.3 +/- 6.3 h for M2, respectively).",Effect of filgrastim on the pharmacokinetics of MX2 hydrochloride in patients with advanced malignant disease. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9523740/),h,12.3,138444,DB00099,Filgrastim
,7527590,AUC,The first cohort of patients received an AUC of 5 mg/mL x min every 3 weeks.,Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7527590/),[mg] / [min·ml],5,151242,DB00099,Filgrastim
,7527590,AUCs,"Subsequently four additional cohorts received AUCs of 5, 7, 9, and 8 every 2 weeks.",Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7527590/),,5,151243,DB00099,Filgrastim
,7527590,AUCs,"Subsequently four additional cohorts received AUCs of 5, 7, 9, and 8 every 2 weeks.",Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7527590/),,7,151244,DB00099,Filgrastim
,7527590,AUCs,"Subsequently four additional cohorts received AUCs of 5, 7, 9, and 8 every 2 weeks.",Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7527590/),,9,151245,DB00099,Filgrastim
,7527590,AUCs,"Subsequently four additional cohorts received AUCs of 5, 7, 9, and 8 every 2 weeks.",Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7527590/),,8,151246,DB00099,Filgrastim
,7527590,AUC,The dose-limiting toxicity was thrombocytopenia and occurred at an AUC of 9.,Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7527590/),,9,151247,DB00099,Filgrastim
,7527590,AUC,Most patients could complete treatment at an AUC of 7.,Carboplatin and granulocyte colony-stimulating factor as first-line treatment for epithelial ovarian cancer: a phase I dose-intensity escalation study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7527590/),,7,151248,DB00099,Filgrastim
,25894719,AUC0-inf,"Pegfilgrastim mean AUC0-inf values for the on-body injector (n = 125) and manual injection (n = 128) were 10,900 and 11,100 h ng/mL, respectively; mean C max values were 248 and 262 ng/mL, respectively.",Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25894719/),[h·ng] / [ml],"10,900",155034,DB00099,Filgrastim
,25894719,AUC0-inf,"Pegfilgrastim mean AUC0-inf values for the on-body injector (n = 125) and manual injection (n = 128) were 10,900 and 11,100 h ng/mL, respectively; mean C max values were 248 and 262 ng/mL, respectively.",Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25894719/),[h·ng] / [ml],"11,100",155035,DB00099,Filgrastim
,25894719,C max,"Pegfilgrastim mean AUC0-inf values for the on-body injector (n = 125) and manual injection (n = 128) were 10,900 and 11,100 h ng/mL, respectively; mean C max values were 248 and 262 ng/mL, respectively.",Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25894719/),[ng] / [ml],248,155036,DB00099,Filgrastim
,25894719,C max,"Pegfilgrastim mean AUC0-inf values for the on-body injector (n = 125) and manual injection (n = 128) were 10,900 and 11,100 h ng/mL, respectively; mean C max values were 248 and 262 ng/mL, respectively.",Comparison of pharmacokinetics and safety of pegfilgrastim administered by two delivery methods: on-body injector and manual injection with a prefilled syringe. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25894719/),[ng] / [ml],262,155037,DB00099,Filgrastim
,24962521,maximum tolerated dose,The maximum tolerated dose was identified as 24 mg/m(2) due to dose-limiting thrombocytopenia in two patients receiving 30 mg/m(2) .,"Phase 1 evaluation of EZN-2208, a polyethylene glycol conjugate of SN38, in children adolescents and young adults with relapsed or refractory solid tumors. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24962521/),[mg] / [m(2],24,168431,DB00099,Filgrastim
,32820861,tmax,"Obtained values for tmax (∼4 hours), tmax,E (∼15 hours), and elimination half-life (∼3.5 hours) were comparable between 2 treatment groups.",Biosimilarity Assessment of 2 Filgrastim Therapeutics in Healthy Volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32820861/),h,∼4,184000,DB00099,Filgrastim
,32820861,elimination half-life,"Obtained values for tmax (∼4 hours), tmax,E (∼15 hours), and elimination half-life (∼3.5 hours) were comparable between 2 treatment groups.",Biosimilarity Assessment of 2 Filgrastim Therapeutics in Healthy Volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/32820861/),h,∼3.5,184001,DB00099,Filgrastim
,21723892,half-life,Simultaneous pharmacokinetic analysis of released and encapsulated G-CSF plasma levels showed that the G-CSF release occurs with the first-order kinetics and the half-life is 4.8h.,Prolonged circulation and in vivo efficacy of recombinant human granulocyte colony-stimulating factor encapsulated in polymeric micelles. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21723892/),h,4.8,184996,DB00099,Filgrastim
,10986062,CL(DOC),"Mean +/- SD CL(DOC) in cycles 1 and 2 were 75.9 +/- 79.6 L/h/m(2) and 29.2 +/- 17.3 L/h/m(2), respectively (P: <.046).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),[h·l] / [m(2],75.9,188761,DB00099,Filgrastim
,10986062,CL(DOC),"Mean +/- SD CL(DOC) in cycles 1 and 2 were 75.9 +/- 79.6 L/h/m(2) and 29.2 +/- 17.3 L/h/m(2), respectively (P: <.046).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),[h·l] / [m(2],29.2,188762,DB00099,Filgrastim
,10986062,CL(TPT),"Mean +/- SD CL(TPT) in cycles 1 and 2 were 8.5 +/- 4.4 L/h/m(2) and 9.3 +/- 3.4 L/h/m(2), respectively (P: >. 05).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),[h·l] / [m(2],8.5,188763,DB00099,Filgrastim
,10986062,CL(TPT),"Mean +/- SD CL(TPT) in cycles 1 and 2 were 8.5 +/- 4.4 L/h/m(2) and 9.3 +/- 3.4 L/h/m(2), respectively (P: >. 05).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),[h·l] / [m(2],9.3,188764,DB00099,Filgrastim
,10986062,neutrophil nadir,"Mean +/- SD neutrophil nadir in cycles 1 and 2 were 4,857 +/- 6, 738/microL and 2,808 +/- 4,518/microL, respectively (P: =.02).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),1/[μl],"4,857",188765,DB00099,Filgrastim
,10986062,neutrophil nadir,"Mean +/- SD neutrophil nadir in cycles 1 and 2 were 4,857 +/- 6, 738/microL and 2,808 +/- 4,518/microL, respectively (P: =.02).",Pharmacokinetic and pharmacodynamic study of the combination of docetaxel and topotecan in patients with solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10986062/),1/[μl],"2,808",188766,DB00099,Filgrastim
,19825950,maximum tolerated dose,The maximum tolerated dose without G-CSF is 500 mg/m(2).,A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825950/),mg,500,189436,DB00099,Filgrastim
,19825950,half-life,Danusertib showed dose-proportional pharmacokinetics in parts 1 and 2 with a median half-life of 18 to 26 hours.,A phase I dose-escalation study of danusertib (PHA-739358) administered as a 24-hour infusion with and without granulocyte colony-stimulating factor in a 14-day cycle in patients with advanced solid tumors. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19825950/),h,18 to 26,189437,DB00099,Filgrastim
,15900288,clearance,"The population estimates (+/-SE) for clearance and central volume of distribution were 5.17 +/- 0.49 L/h and 16.9 +/- 3.79 L, respectively.",A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900288/),[l] / [h],5.17,198518,DB00099,Filgrastim
,15900288,central volume of distribution,"The population estimates (+/-SE) for clearance and central volume of distribution were 5.17 +/- 0.49 L/h and 16.9 +/- 3.79 L, respectively.",A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900288/),l,16.9,198519,DB00099,Filgrastim
,15900288,maximum effect,"The population estimates (+/-SE) of maximum effect, concentration causing 50% of maximum response, and equilibration time were 12.6 +/- 4.89, 53.6 +/- 11.9 mug/L, and 5.37 +/- 1.31 hours, respectively.",A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900288/),[μg] / [l],12.6,198520,DB00099,Filgrastim
,15900288,concentration causing 50% of maximum response,"The population estimates (+/-SE) of maximum effect, concentration causing 50% of maximum response, and equilibration time were 12.6 +/- 4.89, 53.6 +/- 11.9 mug/L, and 5.37 +/- 1.31 hours, respectively.",A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900288/),[μg] / [l],53.6,198521,DB00099,Filgrastim
,15900288,concentration causing 50% of maximum response,"The population estimates (+/-SE) of maximum effect, concentration causing 50% of maximum response, and equilibration time were 12.6 +/- 4.89, 53.6 +/- 11.9 mug/L, and 5.37 +/- 1.31 hours, respectively.",A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900288/),h,5.37,198522,DB00099,Filgrastim
,15900288,time,"The population estimates (+/-SE) of maximum effect, concentration causing 50% of maximum response, and equilibration time were 12.6 +/- 4.89, 53.6 +/- 11.9 mug/L, and 5.37 +/- 1.31 hours, respectively.",A pharmacokinetic-pharmacodynamic model for the mobilization of CD34+ hematopoietic progenitor cells by AMD3100. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15900288/),h,5.37,198523,DB00099,Filgrastim
,19902989,bioavailability,Filgrastim was found to exhibit parallel absorption with first- and zero-order kinetics and bioavailability of 69.1%.,Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19902989/),%,69.1,206125,DB00099,Filgrastim
,19902989,equilibrium dissociation constant (K(d)),The equilibrium dissociation constant (K(d)) was estimated as 16.38 pM.,Population pharmacokinetic modelling of filgrastim in healthy adults following intravenous and subcutaneous administrations. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19902989/),pM,16.38,206126,DB00099,Filgrastim
,26668251,time to ANC recovery,"Between-group efficacy parameters were comparable except for time to ANC recovery in cycle 1 (40 mg of balugrastim, 2.0 days; 50 mg of balugrastim, 2.1; pegfilgrastim, 2.6).",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),d,2.0,208259,DB00099,Filgrastim
,26668251,time to ANC recovery,"Between-group efficacy parameters were comparable except for time to ANC recovery in cycle 1 (40 mg of balugrastim, 2.0 days; 50 mg of balugrastim, 2.1; pegfilgrastim, 2.6).",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),,2,208260,DB00099,Filgrastim
,26668251,terminal elimination half-life,"Median terminal elimination half-life was ≈37 hours for 40 mg of balugrastim, ≈36 for 50 mg of balugrastim, and ≈45 for pegfilgrastim.",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),h,37,208261,DB00099,Filgrastim
,26668251,terminal elimination half-life,"Median terminal elimination half-life was ≈37 hours for 40 mg of balugrastim, ≈36 for 50 mg of balugrastim, and ≈45 for pegfilgrastim.",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),,36,208262,DB00099,Filgrastim
,26668251,terminal elimination half-life,"Median terminal elimination half-life was ≈37 hours for 40 mg of balugrastim, ≈36 for 50 mg of balugrastim, and ≈45 for pegfilgrastim.",A Phase III Study of Balugrastim Versus Pegfilgrastim in Breast Cancer Patients Receiving Chemotherapy With Doxorubicin and Docetaxel. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/26668251/),,45,208263,DB00099,Filgrastim
<,19395467,absolute neutrophil counts,Eighteen Japanese lung cancer patients who had experienced severe neutropenia (absolute neutrophil counts <0.5 x 10(9) cells/l) were enrolled.,A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19395467/),,0.5 x,212909,DB00099,Filgrastim
less,11773150,AN,Ro 25-8315 100 microg/kg was more effective than filgrastim in reducing the number of patients with an ANC less than 0.5 x 10(9)/L on day +12 after chemotherapy.,"Randomized, controlled, dose-range study of Ro 25-8315 given before and after a high-dose combination chemotherapy regimen in patients with metastatic or recurrent breast cancer patients. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11773150/),,0.,215001,DB00099,Filgrastim
> or =,14692520,time to absolute neutrophil count (ANC) recovery,"The pharmacokinetics of pegfilgrastim were characterized and the duration of grade 4 neutropenia, time to absolute neutrophil count (ANC) recovery to > or = 2.0 x 10(9)/l, neutrophil nadir, and incidence of febrile neutropenia were determined in the first 21-day chemotherapy cycle.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),,2.0 x 10(9),234938,DB00099,Filgrastim
,14692520,duration of grade 4 neutropenia,The incidence of grade 4 neutropenia in cycle 1 was 43% with a mean (SD) duration of grade 4 neutropenia value of 1.0 (1.4) day.,Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),d,1.0,234939,DB00099,Filgrastim
,14692520,time to ANC recovery,"The median [quartiles] time to ANC recovery was 10 [9, 11] days.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),d,10,234940,DB00099,Filgrastim
,14692520,terminal half-life,"After the second peak, concentration of pegfilgrastim declined linearly with a median terminal half-life of approximately 42 h.",Fixed-dose pegfilgrastim is safe and allows neutrophil recovery in patients with non-Hodgkin's lymphoma. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/14692520/),h,42,234941,DB00099,Filgrastim
,29318653,systemic half-lives,The systemic half-lives of filgrastim (2.6 h) and pegfilgrastim (10.1 h) were as expected.,Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29318653/),h,2.6,240835,DB00099,Filgrastim
,29318653,systemic half-lives,The systemic half-lives of filgrastim (2.6 h) and pegfilgrastim (10.1 h) were as expected.,Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29318653/),h,10.1,240836,DB00099,Filgrastim
,29318653,half-life,"The effective half-life of chemotherapy was 9.6 h, with a 2-day killing effect.",Pharmacokinetic-pharmacodynamic modelling of neutrophil response to G-CSF in healthy subjects and patients with chemotherapy-induced neutropenia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29318653/),h,9.6,240837,DB00099,Filgrastim
,9220292,area under the concentration-time curve (AUC),Twenty-three patients were treated with paclitaxel at doses ranging from 175 to 225 mg/m2 followed by carboplatin targeting area under the concentration-time curve (AUC) 7 or 9 mg/mL.min every 3 weeks.,Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9220292/),[mg] / [min·ml],7,244001,DB00099,Filgrastim
,9220292,area under the concentration-time curve (AUC),Twenty-three patients were treated with paclitaxel at doses ranging from 175 to 225 mg/m2 followed by carboplatin targeting area under the concentration-time curve (AUC) 7 or 9 mg/mL.min every 3 weeks.,Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9220292/),[mg] / [min·ml],9,244002,DB00099,Filgrastim
,9220292,AUC,"A high rate of intolerable, mutually exclusive toxicities, consisting primarily of thrombocytopenia, as well as neutropenia, nausea and vomiting, and mucositis, precluded escalation of carboplatin above a targeted AUC of 7 mg/mL.min with paclitaxel 225 mg/m2, which approaches the maximum tolerated dose (MTD) of paclitaxel given as a single agent on a 3-hour schedule.",Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9220292/),[mg] / [min·ml],7,244003,DB00099,Filgrastim
,9220292,AUC,The recommended doses for subsequent clinical trials are paclitaxel 225 mg/m2 as a 3-hour infusion followed by carboplatin at a targeted AUC of 7 mg/mL.min.,Phase I study of paclitaxel on a 3-hour schedule followed by carboplatin in untreated patients with stage IV non-small cell lung cancer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9220292/),[mg] / [min·ml],7,244004,DB00099,Filgrastim
,11350887,MTD,The MTD of DP without PSC 833 was 35 mg/m(2) doxorubicin and 150 mg/m(2) paclitaxel.,"A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350887/),mg,35,257766,DB00099,Filgrastim
,11350887,MTD,The MTD of DPV without G-CSF was 12.5 mg/m(2) doxorubicin and 70 mg/m(2) paclitaxel.,"A phase I trial of doxorubicin, paclitaxel, and valspodar (PSC 833), a modulator of multidrug resistance. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11350887/),mg,12.5,257767,DB00099,Filgrastim
,9737832,time to peak ANC,"The time to peak ANC on day 10 was approximately 9 hours, with a daily ANC profile in all four dose groups that was similar to the profile on day 1.",Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9737832/),h,9,268383,DB00099,Filgrastim
